Bayer Spend On Start-Ups Growing By Leaps And Bounds
Ramps Up Investment Cashpile
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
You may also be interested in...
The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.
Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.